These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Idarubicin-anti-CD3: a new immunoconjugate that induces alloantigen-specific tolerance in mice. Mottram PL; Han WR; Murray-Segal LJ; Mandel TE; Pietersz GA; McKenzie IF Transplantation; 1997 Sep; 64(5):684-90. PubMed ID: 9311703 [TBL] [Abstract][Full Text] [Related]
4. Tolerance in baboon kidney transplantation with total lymphoid irradiation (TLI) and anti-CD3/CD4-idarubicin conjugates. Myburgh JA; Smit JA; Pieterz GA; Ling S; Sandrin MS; McKenzie IF Transplantation; 2001 Sep; 72(6):1150-2. PubMed ID: 11579315 [TBL] [Abstract][Full Text] [Related]
5. Evidence that an anthracycline-anti-CD8 immunoconjugate, idarubicin-anti-Ly-2.1, prolongs heart allograft survival in mice. Mottram PL; Pietersz GA; Smyth MJ; Purcell LJ; Clunie GJ; McKenzie IF Transplantation; 1993 Mar; 55(3):484-90. PubMed ID: 8456465 [TBL] [Abstract][Full Text] [Related]
6. Anti-T cell monoclonal antibodies for in vivo treatment of cardiac allograft rejection in mice. Mottram PL; Smyth M; Pietersz GA; Clunie GJ; McKenzie IF Transplant Proc; 1989 Feb; 21(1 Pt 1):1020-1. PubMed ID: 2650063 [No Abstract] [Full Text] [Related]
7. Immunosuppression by anti-CD8 (Ly-2.1) MAb conjugated to idarubicin: studies in the mouse heart graft model. Mottram PL; Pietersz GA; Purcell LJ; Clunie GJ; McKenzie IF Transplant Proc; 1990 Oct; 22(5):2111-2. PubMed ID: 2120812 [No Abstract] [Full Text] [Related]
8. Induction therapy with an immunomodulatory CD2 antibody does not inhibit allograft vasculopathy after rat heart transplantation. Dengler TJ; Szabo G; Amann K; Nottmeyer W; Vahl C; Hagl S; Zimmermann R Transplant Proc; 1998 May; 30(3):868-70. PubMed ID: 9595130 [No Abstract] [Full Text] [Related]
9. Immunosuppression by aminopterin or idarubicin conjugated to anti-CD8 in the mouse heart allograft model. Mottram PL; Pietersz GA; Purcell LJ; Krauer K; McKenzie IF Transplant Proc; 1992 Oct; 24(5):2301. PubMed ID: 1413068 [No Abstract] [Full Text] [Related]
10. Deletion of graft reactive cells by idarubicin-anti-CD8 (Ly-2.1) immunoconjugate: studies in the mouse heart graft model. Mottram PL; Pietersz GA; Purcell LJ; Krauer K; Clunie GJ; McKenzie IF Transplant Proc; 1991 Feb; 23(1 Pt 1):499-500. PubMed ID: 1899311 [No Abstract] [Full Text] [Related]
11. Prolongation of fetal pancreas allograft survival in mice treated with anti-IL-2 receptor monoclonal antibody (PC61) conjugated with idarubicin. Koulmanda M; Pietersz G; McKenzie IF; Mandel TE Transplant Proc; 1990 Oct; 22(5):2113-4. PubMed ID: 2219312 [No Abstract] [Full Text] [Related]
12. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects. Chavin KD; Qin L; Lin J; Kaplan AJ; Bromberg JS Transplantation; 1993 Apr; 55(4):901-8. PubMed ID: 8097344 [TBL] [Abstract][Full Text] [Related]
13. Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy. Plain KM; Chen J; Merten S; He XY; Hall BM Transplantation; 1999 Feb; 67(4):605-13. PubMed ID: 10071035 [TBL] [Abstract][Full Text] [Related]
14. Treatment of mice with anti-CD3 mAb induces endothelial vascular cell adhesion molecule-1 expression. Bergese SD; Pelletier RP; Ohye RG; Vallera DA; Orosz CG Transplantation; 1994 Mar; 57(5):711-7. PubMed ID: 7511256 [TBL] [Abstract][Full Text] [Related]
15. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872 [TBL] [Abstract][Full Text] [Related]